替沃扎尼用于治疗肾细胞癌：患者选择与展望
Tivozanib for the treatment of renal cell carcinoma: patient selection and perspectives.
作者信息
Rodenburg R J, Eskens Falm
机构信息
Erasmus MC Cancer Institute, Department of Medical Oncology, Rotterdam, The Netherlands.
出版信息
Int J Nephrol Renovasc Dis. 2019 May 15;12:137-141. doi: 10.2147/IJNRD.S169056. eCollection 2019.
Tivozanib is an oral selective vascular endothelial growth factors receptor (VEGFR) tyrosine kinase inhibitor that is recently approved by the European Medicines Agency for the treatment of previously untreated patients with metastatic renal cell carcinoma (mRCC) as well as for those patients with disease progression during or after cytokine therapy. Nowadays, in first-line and second-line treatment of mRCC, there is an abundance of options, mainly consisting of VEGFR-directed tyrosinekinase inhibitors. This review focusses on the role of tivozanib with respect to patient selection and future perspectives in this fast-changing landscape.
替沃扎尼是一种口服选择性血管内皮生长因子受体（VEGFR）酪氨酸激酶抑制剂，最近已获欧洲药品管理局批准，用于治疗既往未接受过治疗的转移性肾细胞癌（mRCC）患者以及细胞因子治疗期间或之后疾病进展的患者。如今，在mRCC的一线和二线治疗中，有大量选择，主要包括VEGFR靶向酪氨酸激酶抑制剂。本综述重点关注替沃扎尼在这一快速变化的领域中关于患者选择的作用及未来前景。
Zotero 插件